We Are Not Ready to Edit Human Embryos Yet
By J. Craig Venter,
Time
| 02. 02. 2016
Untitled Document
Unless we have sufficient knowledge and wisdom we should not proceed
Discussions on human genome modifications to eliminate disease genes and/or for human enhancement are not new and have been common place since the first discussions on sequencing the human genome occurred in the mid 1980’s. Many a bioethicist has made their careers from such discussions, and currently on Amazon there are dozens of books on a wide range of human enhancement topics including those that predict that editing our genes will lead to the end of humanity. There are also thousands of news stories on the new DNA editing tools called CRISPR.
So why is genome editing so different? If we can use CRISPR techniques to change the letters of the genetic code known to be associated with rare genetic disorders such as Tay-Sachs disease, Huntington’s disease, cystic fibrosis, cycle cell anemia or ataxia telangiectasia, why wouldn’t we just do so and eliminate the diseases from human existence? The answer is both simple and complex at the same time: just because the techniques have become easier to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...